Yale University is partnering with CROs to provide drug discovery services to awardees of the Blavatnik Fund for Innovation – which aims to bridge the gap between early-stage research and product development.
RxCelerate is opening its first office in the US to be closer to clients and meet a "huge demand" for drug discovery and development services in the greater Boston area.
WuXi Biologics and CANbridge Pharmaceutical have entered into a long-term partnership to develop and commercialize a portfolio of biotherapeutics for rare diseases.
Evotec AG and Ferring Pharmaceuticals are collaborating to discover and develop new small molecule therapies for the treatment of fertility and gynaecological conditions.
The platform will be designed to help life sciences organizations improve productivity, efficiency, and innovation in early stage drug development, says Accenture executive.
Evotec and Almirall are using a novel approach to disrupt cell signaling to discover and develop first-in-class therapeutics targeting dermatology diseases.
The outsourced service providers have signed a new collaboration agreement to provide global pharmaceutical and biotechnology clients access to electrophysiology and ion channel screening.
The joint drug discovery project announced yesterday will combine Centogene’s genetic testing service offerings with Evotec's iPSC platform and drug discovery capabilities.
The multi-phase collaboration between WuXi AppTec Research Service Division and Cyclica looks to advance polypharmacology in drug discovery using AI-augmented technology.
Antoxerene and investor firm Juvenescence have collaborated to form FoxBio Inc., an offshoot focused on small molecule drug discovery for the pathways of ageing.
Cross-industry discussion is expanding from early discovery to post-licensing challenges – as the nexus of innovation and policy improvements is rapidly changing, says DIA executive.
Charles River has been granted commercial access to AstraZeneca’s high-throughput screening (HTS) and compound management infrastructure, an investment that will help the company "deliver optimal benefit" to its customers, says executive.
Fraunhofer is “redoubling” its efforts to develop new antibiotics and transfer research into clinical trials through a project available to external partners for development.
Biogen and Accenture Labs have collaborated to develop a quantum-enabled molecular comparison application to accelerate drug discovery and ultimately, time to clinic.
AMRI has entered an alliance through which the global contract research and manufacturing organization will gain access to "new avenues of drug discovery."
A US-subsidiary of the Chinese CDMO Porton Fine Chemicals Ltd. has bought the New Jersey based small molecule API contract research organisation, J-STAR Research, Inc.
Sharp Edge Labs will use its propriety biosensor platform to identify lead compounds for Sumitomo Dainippon Pharma – technology that the company says will help focus discussions on outcomes rather than cost.
The Charles Stark Draper Laboratory Inc. has inked a three year partnership with Pfizer to create personalised versions of Draper’s Microphysiological Systems (MPS), for cheaper and more effective preclinical testing.
As part of the company’s continued growth, Charles River’s recent partnership with The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) will work to accelerate drug development.
Phyton Biotech has developed a cell based way of making thapsigargin, a cytotoxic plant extract that is being developed for the treatment of cancer by Inspyr Therapeutics.
As part of a recent survey, 62% of respondents said they are more likely to engage a clinical research organization (CRO) partner for clinical research than they were five years ago.
More drug discovery work will be outsourced this year according to a report which suggests pharmaceutical industry desire to reduce the risk of failure and cut costs persists.
Researchers have created the first robotically driven experimentation system which reduces the number of necessary experiments throughout drug discovery by 70%.
With the expectation of new regulatory guidelines, and the need for increased productivity, companies will need to become “comfortable with data,” says Quintiles executive.
AMRI has opened a drug discovery center, citing growing customer demand for biology, high-throughput screening, in vitro pharmacology, and medicinal chemistry at a single site.
Evotec has been hired to manage candidate drug compounds by the US National Cancer Institute (NCI) under an agreement the CRO hopes will help it win further contracts.
Computational drug designer Schrödinger has entered into a five-year early drug discovery collaboration with Sanofi in which Schrödinger will provide target analysis and validation to lead identification and lead optimization for as many as ten drug discovery...
The strategic partnership comes with Sanofi providing €250m to Evotec, including €40m upfront, as part of efforts to discover new drug candidates, including in the area of oncology, and specifically at Sanofi’s R&D site in Toulouse, France.
Fluctuations in regulations over the past few years have reduced the number of clinical trials run on the subcontinent, but now governing bodies are looking at new ways to attract trials and further control the industry.
Charles River Laboratories is nearing the acquisition of an early-stage drug discovery company, CEO James Foster told attendees at the Leerink Swann Global Healthcare Conference last week.
Evotec and Sanofi have entered into exclusive negotiations for a major strategic partnership that will include a €250m ($310m) minimum guaranteed commitment from Sanofi over the next five years.
MPI Research announced Monday it has acquired the assets of Kalamazoo, Michigan-based CRO Jasper Clinical Research & Development, which provides early-stage human clinical testing of new drugs for an undisclosed amount.
Evotec has announced positive milestone news this week, revealing that efforts to develop an endometriosis drug with Bayer have moved into preclinical testing.
